Concepedia

Publication | Open Access

Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors

DOIFull Paper Access

14

Citations

35

References

2022

Year

Yuxiang Ma, Furong Liu, Yang Zhang, Qun Chen, Zhiqiang Chen, Qianwen Liu, Yan Huang, Yunpeng Yang, Wenfeng Fang, Ning Xi,
Frontiers in Immunology

Abstract

CT053PTSA has potent antitumor and antiangiogenic activity in preclinical models. In this FIH phase I trial, CT053PTSA was well tolerated and had a satisfactory safety profile. Further trials evaluating the clinical activity of CT053PTSA are ongoing.

References

YearCitations

Page 1